Is Evidation profitable in 2026?

No confirmed profitability data exists since Evidation is private. Aggregator estimates put annual revenue around $63M as of mid 2026 against a $1.11B valuation from its September 2024 raise, but no primary financial filing has ever been disclosed by the company.

Is Evidation's business at risk from a down round?

Evidation's September 23, 2024 Series E-2 was an insider-only top-up of $105M at a reported $1.11B post-money valuation, not a clean external up-round. Combined with flat-to-declining headcount through 2025-2026, this signals possible strain rather than accelerating growth.

Who is Evidation's biggest competitor?

IQVIA and Optum are the dominant real-world evidence incumbents, with IQVIA aggregating over 1.2 billion patient records as of June 2026. Datavant's May 2025 acquisition of peer Aetion also shows consolidation pressure building around smaller RWE players like Evidation.

Could AI replace Evidation?

AI is more likely to feed on Evidation's data than replace it. CEO Leslie Oley Wilberforce said in July 2026 that healthcare is building AI on data designed for a different era, positioning Evidation's 5 million-person consented panel as the substrate foundation models need, not a workflow AI can bypass.

Has Evidation had layoffs?

No confirmed Evidation-specific layoff reports exist as of mid 2026. However, a 2026 Built In tracker describes headcount trajectory as modest or steady rather than rapidly scaling, with some data suggesting possible employee declines through 2025-2026.

Evidation Health, Inc. is privately held and venture-backed, with investors including B Capital Group, Kaiser Permanente Ventures, OMERS, McKesson Ventures, GE Ventures, Section 32, and SV Health Investors. It carries unicorn status near $1.11B valuation as of its September 23, 2024 Series E-2 round.

United States · United States

Evidation

Runs a 5-million-person consented health data panel that pharma and researchers pay to use.

Losing its protection

Assessed 29 July 2026 · Evidence as of 29 July 2026

The structural protection is eroding.

On the recordSince 29 July 2026 · Checkable from Jan 2026 · Every call on the record Checkpoint: Temporal Proteomics Platform launch and early biopharma adoption results

The call

Evidation holds a real participant network that big platforms and pharma still need, but its last raise was insiders-only and growth signals are flat.

Evidation is a company that recruits and manages large groups of people who agree to share their health data for medical research. The company has built up a real advantage over ten years by signing up 5 million people across different health conditions and locking in major clients like Johnson & Johnson and the American Heart Association. However, bigger players like IQVIA and Optum have their own huge patient databases and could copy what Evidation does, and tech companies like Apple and Google already have hundreds of millions of people willing to share health data through their phones and devices. The key question is whether Evidation can speed up its growth by using artificial intelligence to make its research data more valuable, or whether it ends up getting bought by a larger company at a price that doesn't reward current investors.

Why

AI pressure: Unlearn.AI and other synthetic-control-arm generators for clinical trials. AI-generated synthetic patient data could substitute for real recontactable panels in some trial designs, shrinking one use case. Could AI do the core job? Unlikely.

Bigger players: Apple Health and Google Fitbit. Apple and Google already hold hundreds of millions of biometric users and could open a competing research panel with one product decision. Could a giant copy it? Probably.

What protects it. A decade of consented, recontactable participant relationships plus named lock-in with J&J, Apple Heartline, AHA, and BARDA that is hard to rebuild fast.

What would change this call

Evidation's next raise is a clean external up-round vs. another insider-only bridge. Shows whether outside investors still value the growth story or only insiders are propping it up.
Apple, Google or Fitbit launches a research-participant/panel product. Would let a tech giant undercut Evidation's consented-panel distribution advantage.
Named biopharma adoption of Evidation's Temporal Proteomics platform by 2026. Would show revenue growth reaccelerating rather than stalling.

Key numbers

5 million consented participants across 97% of US ZIP codes (n.d.)
$105M Series E-2 at $1.11B valuation, insiders only (2024-09-23)
140+ real-world studies run on the platform (n.d.)

Named risks

Insider-only Series E-2 top-up (Sep 2024) instead of external up-round may signal weak new-investor demand. Severity: high
Flat-to-declining headcount through 2025-2026 across multiple trackers despite new product launches. Severity: medium
Sector consolidation (Datavant-Aetion, May 2025) suggests independents may face acquisition rather than independent scaling. Severity: medium
No primary financial disclosure exists; all revenue and valuation figures rely on unconfirmed aggregator estimates. Severity: medium
Consumer tracking/rewards layer is commoditizable by Apple, WHOOP, and Fitbit at platform scale. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
IQVIA	losing to	Aggregates 1.2B+ patient records vs Evidation's ~5M consented panel, as of June 2026
Datavant/Aetion	contesting	Datavant acquired RWE peer Aetion in May 2025, showing consolidation risk around independents
Optum	losing to	Named market leader in RWE solutions with larger claims/EHR data network, per June 2026 report
Apple Health/WHOOP/Fitbit	gaining on	Consumer wearable platforms hold hundreds of millions of biometric users, one product step from research-panel competition
Komodo Health	contesting	330M+ patient claims/clinical data platform competing in adjacent RWE analytics space, cited November 2024

Questions people ask

Is Evidation profitable in 2026?: No confirmed profitability data exists since Evidation is private. Aggregator estimates put annual revenue around $63M as of mid 2026 against a $1.11B valuation from its September 2024 raise, but no primary financial filing has ever been disclosed by the company.
Is Evidation's business at risk from a down round?: Evidation's September 23, 2024 Series E-2 was an insider-only top-up of $105M at a reported $1.11B post-money valuation, not a clean external up-round. Combined with flat-to-declining headcount through 2025-2026, this signals possible strain rather than accelerating growth.
Who is Evidation's biggest competitor?: IQVIA and Optum are the dominant real-world evidence incumbents, with IQVIA aggregating over 1.2 billion patient records as of June 2026. Datavant's May 2025 acquisition of peer Aetion also shows consolidation pressure building around smaller RWE players like Evidation.
Could AI replace Evidation?: AI is more likely to feed on Evidation's data than replace it. CEO Leslie Oley Wilberforce said in July 2026 that healthcare is building AI on data designed for a different era, positioning Evidation's 5 million-person consented panel as the substrate foundation models need, not a workflow AI can bypass.
Has Evidation had layoffs?: No confirmed Evidation-specific layoff reports exist as of mid 2026. However, a 2026 Built In tracker describes headcount trajectory as modest or steady rather than rapidly scaling, with some data suggesting possible employee declines through 2025-2026.
Who owns Evidation?: Evidation Health, Inc. is privately held and venture-backed, with investors including B Capital Group, Kaiser Permanente Ventures, OMERS, McKesson Ventures, GE Ventures, Section 32, and SV Health Investors. It carries unicorn status near $1.11B valuation as of its September 23, 2024 Series E-2 round.

Timeline

2026-01-08Launched Temporal Proteomics Platform, an AI-enabled biospecimen platform for autoimmune research
2025-12-22Launched Evidation Everyone Registry cohort engine leveraging 5M+ members
2025-12-02Appointed Dr. Ghazanfar Khan as Chief Medical Officer for AI discovery efforts
2025-05-01Datavant acquired RWE peer Aetion, signaling sector consolidation
2025-03-06Christine Lemke stepped down as CEO; Leslie Oley Wilberforce became first non-founder CEO
2025-03-06Announced new partnership with the American Heart Association
2024-09-23Closed insider-only Series E-2 of $105M at $1.11B post-money valuation
2021-03-22Closed $153M Series E co-led by OMERS Growth Equity and Kaiser Permanente Group Trust
2020-07-01Closed $45M Series D led by B Capital Group
2015-01-01Closed ~$6.2M Series A led by Rock Health and Asset Management Ventures

Revision history

29 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

American Airlines Group Wayfair Safe Superintelligence Inc.